Application of dipeptidyl peptidase 4 as a diagnostic marker or therapeutic target for RA-ILD

By discovering the important role of dipeptidyl peptidase-4 in RA-ILD, as a diagnostic marker and therapeutic target, the difficulties in diagnosis and treatment of RA-ILD were solved, the diagnostic accuracy and therapeutic effect were improved, and the drugs were reduced Side effects provide new treatment ideas.

CN118360383BActive Publication Date: 2024-11-22TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410541694.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-30
Publication Date
2024-11-22
Estimated Expiration
2044-04-30

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively diagnose and treat rheumatoid arthritis-related interstitial lung disease (RA-ILD), and lacks effective biomarkers and therapeutic targets, resulting in difficulties in diagnosis and treatment, with great side effects of drugs and insufficient diagnostic standards. clear.

Method used

By studying the expression level of dipeptidyl peptidase-4 (DPP4) found that it is significantly elevated in lung tissues of RA-ILD patients, which is positively correlated with the degree of fibrosis, providing DPP4 as a new diagnostic marker and therapeutic target. By inhibiting or knocking out DPP4 gene expression, the pulmonary fibrosis index is reduced and the activation ability of fibroblasts is weakened.

Benefits of technology

It improves the diagnostic sensitivity and specificity of RA-ILD, provides new therapeutic strategies, significantly reduces pulmonary fibrosis indicators, reduces drug side effects, and has important clinical value.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118360383B_ABST
    Figure CN118360383B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biotechnology, and in particular to the application of dipeptidyl peptidase 4 as a diagnostic marker or therapeutic target for RA-ILD. The present invention provides a DPP4 gene or protein, whose expression level in the lung tissue of RA-ILD patients, especially in fibroblasts and myofibroblasts, is significantly increased, and the expression level has a significant positive correlation with the degree of fibrosis in the lung tissue of RA-ILD patients, indicating the importance of DPP4 in regulating fibrosis in the lung tissue of RA-ILD patients; in addition, the expression level and fibrosis score of lung tissue fibrosis-related indicators are reduced after knocking out DPP4, and the activation and differentiation ability of primary lung fibroblasts is weakened, highlighting the inhibitory effect of inhibiting DPP4 expression on pulmonary fibrosis. Therefore, dipeptidyl peptidase 4 can be used as a new diagnostic marker and therapeutic target for RA-ILD, providing new ideas and strategies for the diagnosis, evaluation and clinical treatment of RA-ILD-related diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to the application of dipeptidyl peptidase 4 as a diagnostic marker or therapeutic target for RA-ILD. Background Art

[0002] Interstitial lung disease (ILD) can be seen in a variety of connective tissue diseases (CTD). It is one of the most common clinical complications of CTD. It can be a concomitant disease in patients who have been diagnosed with CTD. Sometimes it is the first or even the only clinical manifestation of CTD. It can also occur as a complication during the treatment of CTD. The morbidity and mortality of CTD-related ILD (CTD-ILD) are high. Some ILD patients may progress to advanced pulmonary fibrosis and then respiratory failure, which seriously affects the quality of life of patients, or even their lives.

[0003] Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that often manifests as peripheral symmetrical arthritis and erosive synovitis, leading to joint and bone destruction, deformity, loss of function, and even affecting the patient's life. About 70% of RA patients will experience lung symptoms, which is called RA-related interstitial lung disease (RA-ILD). RA-ILD is mainly composed of two pathological types: usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP). Citrullinated proteins may be an important part of the pathogenesis of RA-ILD and may indicate the starting site of RA-ILD. In addition, many mechanisms are involved in the pathogenesis of RA-ILD, including genes, autoimmune reactions triggered by post-transcriptional modifications (citrullination modifications), immune cell disorders, cytokines, and signaling pathways. All these mechanisms can be summarized as follows: environmental factors (smoking or pathogen infection) can cause oxidative stress, followed by inflammatory responses, post-transcriptional modification changes, and immune responses. Many cytokines, including growth factors, can cause fibroblast differentiation and proliferation, accompanied by the activation of a series of pro-fibrotic signaling pathways and the release of pro-fibrotic cytokines, leading to the occurrence of pulmonary fibrosis, thus causing the association between inflammation and fibrosis. At the same time, matrix metalloproteinases released by damaged epithelial cells can cause cell aggregation, cytokine activation, and the release of pro-fibrotic mediators, thereby initiating cross-linking between inflammatory responses and tissue remodeling pathways.

[0004] At present, the pathogenesis of RA-ILD is more based on hypotheses derived from observational studies, and there are few studies on its intervention. Its pathogenesis and treatment strategies have always been the focus of research. Immunosuppression (such as immunosuppressants mycophenolate mofetil, azathioprine, cyclophosphamide, tacrolimus, cyclosporine A) is the mainstream treatment principle for CTD-ILD patients. However, the current treatment plans are based on experience accumulation and observational studies, as well as inferred from relatively high-quality SSc-ILD clinical research results. Since observational studies or case reports have publication bias, the effectiveness of these treatments for RA-ILD cannot be concluded. In addition, immunosuppressive treatment has serious adverse reactions. Antifibrotic drugs (such as bifenidone and imatinib) can delay the progression of lung disease in patients with CTD-ILD. However, no studies have yet explored their feasibility for use in patients with RA-ILD. Therefore, research on the pathogenesis of RA-ILD and the search for new therapeutic targets are urgently needed. A better understanding of RA-ILD can achieve precise treatment and reduce drug side effects. In addition, there is still a lack of effective consensus on the diagnostic criteria for RA-ILD. Finding new biomarkers is also crucial for the early diagnosis and prognosis assessment of RA-ILD patients, and is of great significance for reducing their mortality rate and improving the quality of life of patients. Summary of the invention

[0005] In response to the above-mentioned technical problems in the prior art, the present invention provides a dipeptidyl peptidase-4 gene or protein, whose expression level is significantly increased in the lung tissue of RA-ILD patients, especially in fibroblasts and myofibroblasts, and its expression level has a significant positive correlation with the degree of fibrosis in the lung tissue of RA-ILD patients, indicating the importance of DPP4 in regulating fibrosis in the lung tissue of RA-ILD patients; in addition, after knocking out DPP4, the expression levels of fibrosis-related indicators and fibrosis scores in the lung tissue of the RA-ILD mouse model were reduced, and the activation and differentiation ability of primary lung fibroblasts was weakened, highlighting the inhibitory effect of inhibiting DPP4 expression on pulmonary fibrosis. Therefore, dipeptidyl peptidase-4 can be used as a new diagnostic marker and therapeutic target for RA-ILD, providing new ideas and strategies for the diagnosis, evaluation and clinical treatment of RA-ILD-related diseases. The present invention is specifically implemented through the following technical solutions:

[0006] The first aspect of the present invention provides the use of dipeptidyl peptidase-4 as a diagnostic marker in the preparation of an auxiliary diagnostic reagent or kit for RA-ILD.

[0007] The present invention analyzes the expression characteristics of dipeptidyl peptidase-4 in RA-ILD patients and their mouse models, and finds that dipeptidyl peptidase-4 mRNA and protein are upregulated in the lung tissue of RA-ILD patients, and their expression levels in fibroblasts and myofibroblasts are also significantly increased, and the fibrosis indicators type I collagen α1 (Col1a1), fibronectin (Fn1) and transforming growth factor β1 (Tgfb1 or TGF-β) are significantly positively correlated with the expression level of dipeptidyl peptidase-4 in lung tissue, indicating that the change in the expression level of dipeptidyl peptidase-4 is positively correlated with the progression of fibrosis in RA-ILD patients. Therefore, the expression level of dipeptidyl peptidase-4 can be used as a diagnostic marker for RA-ILD patients (especially fibrosis progression), and the change in its expression level is used for auxiliary diagnosis of RA-ILD patients, which can greatly improve the sensitivity and specificity of diagnosis of related diseases.

[0008] Furthermore, the diagnostic reagent or kit detects the expression level of dipeptidyl peptidase-4 in an in vitro sample of a subject, and an increased expression level of dipeptidyl peptidase-4 indicates that the subject is at risk of developing RA-ILD.

[0009] Furthermore, the in vitro sample is a sample containing lung tissue, especially a sample containing lung tissue fibroblasts or myofibroblasts.

[0010] Furthermore, the diagnostic reagent or kit comprises a primer pair for specifically amplifying the dipeptidyl peptidase-4 gene, the nucleotide sequences of the upstream and downstream primers of the primer pair are as shown in SEQ ID NO.3-4, or comprises an antibody that specifically binds to the dipeptidyl peptidase-4 protein.

[0011] Based on the same inventive concept as above, the second aspect of the present invention provides the use of a reagent for detecting the expression level of dipeptidyl peptidase-4 in the preparation of an auxiliary diagnostic reagent or kit for RA-ILD.

[0012] Furthermore, the reagent for detecting the expression level of dipeptidyl peptidase-4 is selected from at least one of a primer pair that specifically amplifies the dipeptidyl peptidase-4 gene or an antibody that specifically binds to the dipeptidyl peptidase-4 protein.

[0013] The third aspect of the present invention provides the use of dipeptidyl peptidase-4 as a therapeutic target in the preparation of a drug for treating RA-ILD.

[0014] The present invention analyzes the effect of dipeptidyl peptidase-4 on RA-ILD fibrosis, which affects fibroblast function and fibrosis progression. By downregulating the expression level of the DPP4 gene through gene editing methods such as inhibition or knockout, the expression level of Tgfb, an indicator of lung tissue fibrosis in RA-ILD model mice, can be significantly reduced, and the expression levels of Col1a1 and Fn1, hydroxyproline content and fibrosis score can be reduced. Moreover, the activation ability of primary fibroblasts in mouse lungs and the expression of Tgfb receptors are weakened, confirming the inhibitory effect of DPP4 knockout on pulmonary fibrosis. Using dipeptidyl peptidase-4 as a therapeutic target for RA-ILD has a good anti-pulmonary fibrosis effect, which has great practical significance and clinical value.

[0015] Furthermore, the drug includes an agent for downregulating the expression level of dipeptidyl peptidase-4, which is used as an active ingredient of the drug to achieve an anti-pulmonary fibrosis effect by reducing the expression of dipeptidyl peptidase-4 gene or protein, providing a new and effective means for alleviating the progression of pulmonary fibrosis in RA-ILD related diseases.

[0016] Based on the same inventive concept as above, the fourth aspect of the present invention provides the use of an agent for downregulating the expression level of dipeptidyl peptidase-4 in the preparation of a drug for treating RA-ILD.

[0017] Further, the above-mentioned reagent for downregulating the expression level of dipeptidyl peptidase-4 is selected from at least one of a reagent that reduces the expression level of dipeptidyl peptidase-4 mRNA, a reagent that reduces the expression level of dipeptidyl peptidase-4 protein, or a reagent that reduces the activity of dipeptidyl peptidase-4 protein. Further, it is selected from interfering RNA (siRNA) targeting dipeptidyl peptidase-4 mRNA or a guide RNA (sgRNA) for gene knockout, etc. The aforementioned reagents such as siRNA or sgRNA can be designed according to the DPP4 gene, and will not be repeated here.

[0018] Exemplarily, the nucleotide sequence of the interfering RNA is "5'-CCAATGCAACTTCCATACAAA-3'" (see SEQ ID NO.31) or "5'-ACACTCTAACTGATTACTTAA-3'" (see SEQ ID NO.34), and the aforementioned sequence is amplified by the primer pair shown in SEQ ID NO.29-30 or the primer pair shown in SEQ ID NO.32-33 by conventional methods. Restriction sites are designed in the upstream and downstream primers of the aforementioned primer pair, and the amplified product is digested with the corresponding restriction endonuclease to obtain the interfering RNA sequence of the present invention, which is convenient for insertion into an expression vector such as a lentiviral vector for expression.

[0019] Furthermore, the agent for downregulating the expression level of dipeptidyl peptidase-4 is preferably used to inhibit the expression of dipeptidyl peptidase-4 gene in lung tissue, especially in fibroblasts. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings used in describing the embodiments.

[0021] Figure 1 The results of the GSE81292 data set analysis of the present invention; wherein, Figure A is the expression of the Dpp4 gene in the GSE81292 data set, Figure B is the intersection genes obtained by taking the intersection of the differentially expressed genes between SSc-ILD patients and healthy controls in the GSE81292 data set and the Dpp4-related genes, Figure C is a visualization Cytoscape diagram of the correlation of the intersection genes, Figure D is the principal component analysis results of all genes in GSE81292 (left) and the intersection genes (right), and Figure E is the correlation analysis between the Dpp4 gene expression level and fibrosis indicators in the GSE81292 data set;;

[0022] Figure 2 The weight changes and joint scores of mice in different model groups of the present invention at different time points after intraperitoneal injection of PBS or mannan;

[0023] Figure 3 These are lung pathology score graphs of mice in different model groups of the present invention at different time points after intraperitoneal injection of PBS or mannan, wherein Figures A to C are lung inflammation score, lung fibrosis score, and ILD incidence, respectively;

[0024] Figure 4 This is a graph showing the content of lung tissue fibrosis indicators in mice of different model groups injected with PBS or mannan for 12 weeks in the embodiment of the present invention;

[0025] Figure 5 This is a graph showing the content of Th cell-related inflammatory indexes in lung tissue of mice in different model groups of the present invention injected with PBS or mannan for 12 weeks;

[0026] Figure 6 The figures are the DPP4 expression of mice in different model groups injected with PBS or mannan for 12 weeks in the examples of the present invention; wherein, Figure A is the Dpp4 mRNA level in lung tissue, and Figure B is a representative figure of DPP4 immunofluorescence in lung tissue;

[0027] Figure 7 Representative immunofluorescence images of different fibroblasts in lung tissues of mice in different model groups injected with PBS or mannan for 12 weeks in the present invention, and co-stained with DPP4, wherein images AB are lung tissue myofibroblasts and lung tissue myofibroblasts, respectively;

[0028] Figure 8 This is a correlation analysis diagram of the mRNA level of Dpp4 in lung tissue and the mRNA level of fibrosis indexes in SKG mice injected intraperitoneally with mannan for 12 weeks according to the embodiment of the present invention;

[0029] Fig. 9 SKG and SKG×Dpp4 in the embodiments of the present invention - / - Statistical graph of HS score and Aschoff score of lung tissue in mice 12 weeks after intraperitoneal injection of mannan;

[0030] Fig.10 SKG and SKG×Dpp4 in the embodiments of the present invention - / - Statistical chart of lung tissue fibrosis indexes in mice after intraperitoneal injection of mannan for 12 weeks;

[0031] Fig.11 These are graphs showing the ability of lung activation of primary lung fibroblasts of wild-type mice and Dpp4 knockout mice in the embodiments of the present invention; wherein, Figures AC are respectively the expression levels of fibrosis indicators, the statistical graphs of primary fibroblast proliferation ability, and the expression levels of TGF-β receptors. DETAILED DESCRIPTION

[0032] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below in conjunction with the examples. The examples described herein are only used to explain the present invention and are not used to limit the present invention. All the numbers and other numerical values ​​used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the attached claims are approximate values, which may be changed according to the different ideal properties attempted to be obtained. Each numerical parameter should at least be regarded as obtained based on the reported significant figures and by conventional rounding methods. The meaning of similar words such as "include", "comprise", "contain", "have" is non-restrictive, that is, other steps and other ingredients that do not affect the results can be added. "And / or" should be regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" will be regarded as including the following situations: (i) A, (ii) B, and (iii) A and B.

[0033] Dipeptidyl peptidase 4 (DPP4), also known as CD26, is a transmembrane glycoprotein with a molecular weight of 220-240 kDa and is composed of 766 amino acids; it includes a short intracellular domain consisting of 6 amino acids at the N-terminus, a transmembrane domain consisting of 22 amino acids, and an extracellular domain consisting of 738 amino acids. The extracellular part mainly exerts the activity of dipeptidyl peptidase, which can selectively remove the dipeptide at the N-terminus of peptides whose penultimate amino acids are proline, alanine or serine. At present, research on the role of DPP4 in RA-ILD is very limited.

[0034] The present invention explores the function of the DPP4 gene in rheumatoid arthritis-associated interstitial lung disease (RA-ILD) through bioinformatics research. First, by analyzing the changing characteristics of DPP4 expression in the lung tissue of SSc-ILD patients, it was found that the expression of DPP4 in the lung tissue of SSc-ILD patients was higher than that in healthy controls; the intersection genes obtained by taking the intersection of Dpp4-related genes and SSc-ILD differential genes can better distinguish SSc-ILD patients and their healthy controls, indicating that DPP4 may play an important role in SSc-ILD. In addition, the Dpp4 expression level showed a positive correlation with fibrosis indicators, indicating that DPP4 may promote the fibrosis process of SSc-ILD.

[0035] Furthermore, the RA-ILD mouse model was successfully established by intraperitoneal injection of mannan into C57BL / 6J-SKG mice. This model can well simulate the pathological characteristics of the NSIP subtype of RA-ILD patients, and the level of pulmonary fibrosis in the model mice was significantly increased. This model was then used to explore the expression of DPP4 and its correlation with lung tissue fibrosis. It was found that the expression of DPP4 in the lung tissue of RA-ILD model mice was significantly increased, especially in fibroblasts and myofibroblasts. The expression level of Dpp4 was significantly positively correlated with the fibrosis indicators type I collagen α1 (Col1a1), fibronectin (Fn1) and transforming growth factor β1 (Tgfb1 or TGF-β), indicating that the expression level of DPP4 in lung tissue was positively correlated with the degree of tissue fibrosis, confirming the importance of DPP4 to fibrosis, suggesting that dipeptidyl peptidase-4 can be used as a diagnostic marker for RA-ILD. After Dpp4 was knocked out, the expression level of Tgfb, an indicator of lung tissue fibrosis in RA-ILD mice, was significantly reduced, and the expression levels of Col1a1 and Fn1, as well as the hydroxyproline content and fibrosis score showed a downward trend, which fully highlighted the inhibitory effect of Dpp4 knockout on pulmonary fibrosis. In addition, Dpp4 knockout significantly weakened the activation ability of Tgf-β-induced mouse lung primary fibroblasts, and after Dpp4 knockout, the expression of Tgf-β receptors in lung fibroblasts was reduced, indicating that Dpp4 knockout can inhibit the progression of lung fibrosis in RA-ILD mice by inhibiting the activation of fibroblasts. The above results suggest that DPP4 can be used as a therapeutic target for RA-ILD, which is of great significance for the clinical treatment of rheumatoid arthritis-related interstitial lung disease.

[0036] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples where specific conditions are not specified are usually carried out under conventional conditions, such as the conditions described in the Molecular Cloning Laboratory Guide (Fourth Edition) published by Cold Spring Harbor Laboratory, or the conditions recommended by the manufacturer.

[0037] Experimental animals: The animals used in this study were all from C57BL / 6J background. Wild-type mice and Rag2 - / -Mice were obtained from Alvance Biotechnology Co., Ltd. (Wuhan), and Dpp4 knockout mice and C57BL / 6J-SKG mice were purchased from Shanghai Southern Model Biotechnology Co., Ltd.; among them, C57BL / 6J-SKG mice (hereinafter referred to as SKG mice) were derived from C57BL / 6J-derived mice, which produced gene mutations similar to BALB / c-SKG mice and were used to establish RA-ILD models. BALB / c-SKG is a genetic mouse produced by a mutation in the gene encoding ZAP70 (ζ-chain–associated protein kinase) protein from a BALB / c background. This type of mouse can spontaneously develop arthritis and ILD, mainly due to a point mutation in the Zap70 gene, which causes autoreactive CD4 + The production of T cells, resulting in arthritis and interstitial lung. SKG×Dpp4 - / - The knockout mice were obtained by hybridization of SKG mice and Dpp4 knockout mice. All mice were confirmed by DNA sequencing and gene identification. The mice used were 8-12 weeks old adult mice, raised in the SPF environment of the Experimental Animal Center of the Research Building of Tongji Hospital, and the light time was controlled for 12 hours per day. All mouse-related studies were approved by the Ethics Committee of Tongji Hospital.

[0038] Main experimental reagents: Mannan (derived from Saccharomyces cerevisiae) was purchased from Sigma, USA; eosin solution, hematoxylin solution and red blood cell lysis solution were purchased from Wuhan Solarbio; ELISA plate was purchased from Wuhan Boster; ELISA stop solution was purchased from Wuhan Dakowei; type I collagenase, cDNA Synthesis SuperMix, and qPCR SYBR Green Master Mix were purchased from Wuhan Yeason; hydroxyproline kit was purchased from Nanjing Jiancheng Biotechnology Co., Ltd.; mouse TGF-β cytokine, Mouse IL17A ELISA Kit and MojoSort TMCD4+T cell magnetic bead sorting kit was purchased from Biolegend, USA; neutral gum was purchased from Beijing Zhongshan Jinqiao Company; cell freezing medium was purchased from Wuhan Rod Biotechnology; Gibco fetal bovine serum (FBS), cell stimulator (with protein transport inhibitor), cell fixative and cell fixation / permeabilization agent were purchased from Thermo Fisher, USA; APC-anti-mouse IFN-γ flow cytometry antibody, PE-anti-mouse IL-17A flow cytometry antibody and FITC-anti-mouse CD4 flow cytometry antibody were purchased from Biolegend, USA; mouse DPP4 primary antibody was purchased from Santa Cruze, USA; rabbit mouse α-SMA primary antibody and rabbit mouse CD3 primary antibody were purchased from Abclonal; rabbit mouse FSP1 primary antibody and rabbit mouse Vimentin primary antibody were purchased from Wuhan Boster; Alexa Fluor 488 donkey anti-mouse IgG, Alexa Fluor 488 donkey anti-rabbit IgG, Alexa Fluor 594 donkey anti-mouse IgG and Alexa Fluor 594 donkey anti-rabbit IgG was purchased from Shanghai Yisheng Company.

[0039] Gene and primer: For the Dpp4 gene sequence, see NCBI Gene ID: 13482 or genomic sequence: NC_000068.8 Reference GRCm39 C57BL / 6J (Range: 62160417..62242635complement). The relevant primer sequences are shown in Table 1.

[0040] Table 1 RT-PCR primer information of the present invention embodiment

[0041]

[0042]

[0043] Statistical analysis: The quantitative data obtained in this study are presented in the form of mean ± standard error, and the number of samples for all groups is ≥3. The Shapiro-Wilk test, Anderson-Darling test or Kolmogorov-Smirnov test were used to test whether the data conformed to the normal distribution. For data that conformed to the normal distribution, unpaired t-test or One-way ANOVA was used to test whether the differences between the groups were statistically significant. For data that did not conform to the normal distribution, Mann-Whitney U test and Kruskal-Wallis test and Dunn's post hoc test (KW test) were used. Count data are expressed as n (%). In the correlation analysis, Pearson correlation coefficient analysis was used for data that conformed to the normal distribution, and Spearman correlation coefficient analysis was used for data that did not conform to the normal distribution. Statistical analysis was performed in GraphPad Prism software, version 8. When the bilateral P value was less than 0.05, the difference was statistically significant.

[0044] 1. Transcriptomic analysis showed that DPP4 expression was increased in lung tissues of SSc-ILD patients, and DPP4-related genes could better distinguish SSc-ILD from healthy controls

[0045] The R package “GEO query” was used to download the GSE81292 data from the GEO (Gene expression omnibus) database. This dataset collected lung tissues from 15 SSc-ILD patients and 5 healthy controls (lung tissues removed during lung tumor resection in non-lung cancer patients) for RNA transcriptomics sequencing data for bioinformatics analysis.

[0046] 1.1. Differential gene analysis

[0047] After converting the gene IDs in the GSE81292 dataset, the R language “Limma package” was used to perform differential gene analysis to obtain differentially expressed genes (DEGs) and find the expression of DPP4 in the two groups of people. Significant DEGs were defined as p.adjust<0.05, |LogFC|≥1.

[0048] 1.2. Intersection and visualization of DEGs and DPP4-related genes

[0049] The STRING database (Search tool for the retrieval of interacting genes, link: http: / / string-db.org, version 10.5) was used to search for DPP4-related genes (median confidence, no more than 200 nodes), and the intersection with the DEGs of the GSE81292 dataset was taken, and the obtained intersection genes (IGs) were visualized in Cytoscape.

[0050] 1.3 Principal Component Analysis

[0051] All gene expression matrices and intersection gene expression matrices of the GSE81292 dataset were used to perform principal component analysis (PCA) on the Bioladder online website to observe whether DPP4-related genes can better distinguish SSc-ILD patients from healthy controls.

[0052] 1.4 Correlation Analysis

[0053] The expression of DPP4, ΑSMA, COL1A1 and FN1 in the GSE81292 dataset was extracted, and correlation analysis was performed.

[0054] The GSE81292 dataset was used for analysis (see Figure 1 ) found that compared with healthy controls, 204 genes were upregulated and 258 genes were downregulated in the lung tissues of SSc-ILD patients, totaling 462 DEGs. The Dpp4 expression level in the lung tissues of SSc-ILD patients was significantly higher than that in healthy controls. Subsequently, 201 Dpp4-related genes were found on the STRING database, and these Dpp4-related genes were intersected with the 462 DEGs to obtain 19 intersection genes. The association between these 19 intersection genes was queried on the PPI website and visualized in Cytoscape. The 19 genes were closely correlated. The expression of the 19 intersection genes in the lung tissues of SSc-ILD patients and healthy controls (Control) was further analyzed, and PCA analysis was performed. Figure 1The left side of Figure D shows the PCA analysis of all sequencing results of GSE81292, and the right side shows the PCA analysis of intersection genes. It can be seen that these 19 intersection genes can well distinguish SSc-ILD from healthy controls, indicating that DPP4 plays an important role in SSc-ILD. Since DPP4 plays an important role in fibrosis, and fibrosis is also an important pathological feature of SSc-ILD, the expression of Dpp4 was correlated with the expression of fibrosis indicators. It was found that Dpp4 was significantly positively correlated with fibrosis indicators Col1a1, Fn1 and Tgfb1, indicating that DPP4 plays an important role in SSc-ILD and may promote its fibrosis.

[0055] From the above, we can see that DPP4 expression is elevated in the lung tissue of SSc-ILD patients, and Dpp4-related genes can better distinguish SSc-ILD from healthy controls, suggesting that DPP4 has the potential to be a biomarker.

[0056] 2. Construction and evaluation of rheumatoid arthritis-associated interstitial lung disease (RA-ILD) model

[0057] The research of RA-ILD mostly uses SKG mice (BALB / c-SKG) from BALB / c sources. The gene editing system of BALB / c mice is not perfect yet, so the research on SKG-RA-ILD mostly observes the increase of certain cells or protein expression levels of model mice, and its intervention also mostly adopts inhibitors or monoclonal antibodies, and the research using gene editing technology to explore its pathogenesis is very rare, which brings great limitations to the research of RA-ILD. The research using C57-SKG mice only stays at the arthritis level, and there is no research trying to use C57-SKG mice to establish RA-ILD model. The present embodiment uses mice from C57BL / 6J sources to produce gene mutations similar to BALB / c-SKG mice, explores the feasibility of using C57BL / 6J-SKG mice to establish RA-ILD model, and successfully establishes RA-ILD mouse model. RA-ILD model induction includes: giving 8-12 weeks of C57BL / 6J-SKG mice intraperitoneal injection of 20mg mannan (experimental group) or 200μL sterile PBS (SKG control group), while taking age-sex matched C57BL / 6J wild-type mice intraperitoneally injected with 200μL sterile PBS as wild-type (C57BL / 6J-WT) control. In this example, C57BL / 6J-SKG mice were divided into two groups, one group was intraperitoneally injected with PBS, and their body weight and joints were weighed and scored weekly to observe the probability and severity of spontaneous arthritis and ILD compared with C57BL / 6J-WT; the other group was injected with 20mg mannan to explore whether intraperitoneal injection of mannan can increase the incidence or severity of arthritis and interstitial lung.

[0058] After intraperitoneal injection of mannan / sterile PBS, the mice were weighed and their joints were scored weekly. Joint scoring principles: 0, no joint swelling; 0.1, swelling of one finger or toe; 0.5, mild swelling of the wrist or ankle; 1.0, severe swelling of the wrist or ankle. The scores of all fingers (or toes), wrists and ankles of each mouse's palm and sole were added up to get the total score of each mouse. The mice were killed at different time points (4 weeks, 8 weeks, 12 weeks, 16 weeks and 24 weeks) after modeling, and the lung tissues of the mice were taken for HE and Masson staining to observe the pathological characteristics of the lungs over time; including the following experiments:

[0059] 1) ILD disease severity score: When slicing, cut out the largest section of lung tissue, and after HE staining, use an optical microscope to continuously and overlap the entire section. Then use PS to synthesize the photos into a panoramic view of the largest section of lung tissue, and use ImageJ to analyze the percentage of the lesion area to the entire area. ILD is defined as the occurrence of ILD when the proportion of the lesion area to the total area of ​​the largest section of lung tissue exceeds 10%. ILD severity grading: HS0, 0-10% normal; HS1, 10-30%; HS2, 30-60%; HS3, >60%.

[0060] 2) Pulmonary inflammation score: The pulmonary inflammation score is mainly based on the semi-quantitative grading of inflammatory cell infiltration around the bronchi, bronchioles or blood vessels. Inflammation score level: 0, normal; 1, very few inflammatory cell infiltration; 2, inflammatory cell ring with a width of 1 layer of cells; 3, inflammatory cell ring with a width of 2-4 layers of cells; 4, inflammatory cell ring with a width of ≥4 layers of cells. At least 3 fields of view were randomly selected under a 100x microscope from the largest section of the left lung of each mouse to score the degree of inflammation, and then the average was taken as the pulmonary inflammation score of the mouse.

[0061] 3) Pulmonary fibrosis score: The classic Ashcroft scoring method was used. Fibrosis score: 0, normal lung tissue; 1, mild thickening of the alveolar wall or bronchial wall; 3, moderate thickening of the alveolar wall or bronchial wall, with no obvious damage to the lung tissue structure; 5, aggravated fibrosis, obvious damage to the lung tissue structure, with fibrous bands or small fibrotic areas formed; 7, obvious abnormalities in the lung tissue structure, large areas of fibrosis formed, "honeycomb lung" belongs to this level; 8, all fibrosis areas in one field of view. At least 3 fields of view were randomly selected under a 100x microscope from the largest section of the left lung of each mouse to score its fibrosis degree, and the average was taken as the lung fibrosis score of the mouse.

[0062] 4) Real-time quantitative PCR (RT-PCR): Mouse lung tissue was obtained, RNA was extracted, and reverse transcribed into cDNA using a commercially available kit. The reverse transcription system included: 1 μL RNA (300-500 ng), 3 μL 5×gDNAdigester Mix, and added to 15 μL with enzyme-free water, and then 5 μL 4×Hifair III Super Mix plus was added. Then, SYBR Green and bidirectional primer reaction systems were pre-configured, and the cDNA stock solution was diluted at 1:1 for RT-PCR. The system included: 2 μL cDNA, 0.2 μL primer F (10 μM), 0.2 μL primer R (10 μM), 5 μL HieffqPCR SYBR Green Master Mix, and ddH2O was used to make the volume to 10 μL. The primer sequences of each gene used are shown in Table 1. Select Gapdh as the cell or tissue internal reference gene (constitutive expression), subtract the internal reference CT value of the corresponding sample from the CT value of the target gene to obtain ΔCT, take the average ΔCT of the control group samples, and then subtract the average from the ΔCT of each sample to obtain ΔΔCT. Finally, calculate 2 -ΔΔCT That is, the expression of the index in the sample relative to the control. Unless otherwise specified, the RT-PCR data in this article are analyzed according to this method.

[0063] 5) Determination of hydroxyproline content: refer to the instructions of the kit and calculate according to the following formula, where V hydrolyzate represents the total volume of the hydrolyzate (10 mL), W represents the mass (mg), and A represents the absorbance value at a wavelength of 550 nm:

[0064]

[0065] Figure 2 The weight changes and joint scores of modeling mice in different groups at different time points are shown. In the figure, SKG+PBS means that C57BL / 6J-SKG mice were intraperitoneally injected with PBS, SKG+Mannan means that C57BL / 6J-SKG mice were intraperitoneally injected with mannan (Mannan), and C57BL / 6J+PBS means that C57BL / 6J wild-type mice were intraperitoneally injected with PBS. As can be seen from the figure, C57BL / 6J-SKG mice showed obvious joint swelling within 1 week after intraperitoneal injection of mannan, and no obvious joint swelling was found in mice injected with PBS. Intraperitoneal injection of mannan in C57BL / 6J-SKG mice has little effect on their weight, but can significantly increase the degree of joint swelling.

[0066] From the lung tissue pathology-related staining images, it can be seen that after intraperitoneal injection of mannan in C57BL / 6J-SKG mice, a small amount of inflammatory cell infiltration was found around the small blood vessels and bronchi of the lungs at 4 weeks, while C57BL / 6J-SKG mice without mannan injection showed no obvious inflammation and fibrosis at 4 weeks. At 8 weeks, the lung inflammation of C57BL / 6J-SKG+mannan mice was further aggravated, still mainly around the bronchi and blood vessels, and the alveolar septa were slightly thickened. C57BL / 6J-SKG mice without mannan injection had a small amount of inflammatory cell infiltration around the bronchi and slightly thickened alveolar septa. At 12 weeks, the alveolar septa of C57BL / 6J-SKG+mannan mice were significantly thickened, and fibrotic areas were formed. The alveolar septa of C57BL / 6J-SKG mice without mannan injection were also significantly thickened, but not as significant as those of mice injected with mannan. At 16 weeks, the severity of fibrosis and inflammation in both groups of mice was reduced. At 24 weeks, the fibrosis and inflammation were more severe than at 16 weeks, but less severe than at 12 weeks. Based on the above lung pathology images, the lung inflammation score, lung fibrosis score and the incidence of interstitial lung disease (ILD) were calculated (see Figure 3 ), found that intraperitoneal injection of mannan can promote the incidence of lung inflammation and ILD in C57BL / 6J-SKG mice, and has a tendency to promote pulmonary fibrosis; among them, 70% of mice in the SKG+PBS group had spontaneous ILD (50% were HS1, 20% were HS2, and the proportion of HS3 was 0), and 91.2% of mice in the SKG+mannan group had the disease (7.8% were HS1, 34.8% were HS2, and 8.7% were HS3). Moreover, after 12 weeks, the proportion of lung lesions in C57BL / 6J-SKG mice increased significantly, the spleen index was also higher than that of WT mice and SKG+PBS mice, and the joint score was positively correlated with the HS score of lung tissue.

[0067] The changes in the mRNA levels of Col1a1, Fn1, and Tgfb1 and the content of hydroxyproline in lung tissue fibrosis indicators of the three groups of mice, WT, SKG+PBS, and SKG+mannan, were detected by RT-PCR. Figure 4 It can be seen that mannan induced an increase in the level of lung fibrosis in SKG mice.

[0068] Further testing of the level of lung inflammation in C57BL / 6J-SKG mice 12 weeks after intraperitoneal injection of mannan found that IFN-γ and IL-17A secreted by lung lymphocytes and CD4+T cells increased in SKG mice 12 weeks after intraperitoneal injection of mannan. RT-PCR results showed that the expression levels of Ifng and Il17a in lung tissue also increased, and ELISA detected an increase in plasma IL-17A levels (see Figure 5, from left to right are IFN-γ, IL-17A, Ifng, Il17a and IL-17A level detection diagrams). The above results indicate that the level of Th cell-related inflammation increases.

[0069] In summary, this example successfully used C57BL / 6J-SKG mice to establish a RA-ILD mouse model. After intraperitoneal injection of mannan in C57BL / 6J-SKG mice for 12 weeks, the lung tissue fibrosis index and CD4 + The level of T cell-related inflammation increased significantly, which is consistent with the main characteristics of the SKG mouse disease reported in the literature, and well simulates the pathological characteristics of the NSIP subtype of RA-ILD. The pathological characteristics of NSIP are the mixed existence of inflammation and fibrosis, and NSIP can be divided into different grades according to the severity of inflammation and fibrosis. The coexistence of inflammation and fibrosis in the alveolar septum at 12 weeks in this study is consistent with the complex pathological characteristics of NSIP. Since pulmonary fibrosis peaked 12 weeks after intraperitoneal injection of mannan in C57BL / 6J-SKG, the subsequent model selected the 12-week time point.

[0070] 3. DPP4 expression in lung tissue, fibroblasts and myofibroblasts of RA-ILD mice is increased, and lung tissue DPP4 is positively correlated with fibrosis

[0071] C57BL / 6J-WT mice and C57BL / 6J-SKG mice were divided into three groups, namely WT+PBS, SKG+PBS and SKG+mannan, and then subjected to corresponding stimulation treatments. The total RNA of lung tissue was extracted by Trizol method for 12 weeks and RT-PCR experiment was performed. In addition, the expression of DPP4 in fibroblasts and myofibroblasts in lung tissue was detected by immunofluorescence technology. The immunofluorescence analysis of paraffin sections includes the following steps: dehydrating and paraffin-embedded lung tissues, and then slicing; then baking and dewaxing, using EDTA antigen repair solution, 0.5% membrane permeabilization solution (1.5mL Triton-x100 added to 300mL PBS) to permeate, and blocking solution (50μL donkey / sheep serum + 100μL 10% BSA + 850μL PBS) to block; primary antibody incubation: prepare DPP4 primary antibody diluent according to the instructions, and add primary antibody diluent to make the tissue completely infiltrated; water washing: rinsing with PBS for 5min, rinsing 3 times in total; secondary antibody incubation: diluting anti-mouse green secondary antibody (1:500) and anti-rabbit red secondary antibody (1:300) with PBS according to the instructions, adding 50μL of secondary antibody to each tissue block to ensure that the tissue block is completely infiltrated by the secondary antibody, reacting in the dark for 60min, rinsing with PBS 3 times, each time for 5min; finally sealing. Immunofluorescence images were observed and photographed under a fluorescence upright microscope, and immunofluorescence quantitative analysis was performed using ImageJ.

[0072] Figure 6 The expression of DPP4 in lung tissue of different groups of modeling mice is shown, among which Figure AB is the representative images of DPP4 mRNA level in lung tissue and DPP4 immunofluorescence in lung tissue of C57BL / 6J mice, SKG mice, and SKG mice after intraperitoneal injection of PBS and mannan for 12 weeks (blue: DAPI; green: DPP4, Merge: fusion). It can be seen that compared with WT mice, the expression of DPP4 in lung tissue of SKG mice increased regardless of intraperitoneal injection of PBS or mannan. Immunofluorescence showed that the expression of DPP4 in lung tissue of RA-ILD model mice (SKG+mannan) was higher than that of WT (Control) normal mice.

[0073] Immunofluorescence was further used to detect the changes in DPP4 expression in lung tissue fibroblasts and myofibroblasts of RA-ILD mice in the SKG+mannan group. The results are shown in Figure 7 , where Figures AB are representative images of co-staining immunofluorescence of fibroblasts and myofibroblasts with DPP4, respectively. In the figures, blue: DAPI; green: fibroblasts or myofibroblasts; red: DPP4. It was found that compared with normal mice, the number of fibroblasts and myofibroblasts in the lung tissue of RA-ILD mice increased, and the number of fibroblasts and myofibroblasts expressing DPP4 also increased. The lung tissues of RA-ILD mice were then collected, and the fibrosis indicators (Col1a1, Fn1 and Tgfb1) and Dpp4 expression were detected by RT-PCR, and correlation analysis was performed. Consistent with the GSE81292 dataset, Dpp4 expression in the lung tissue of RA-ILD mice was positively correlated with fibrosis indicators (see Figure 8 ).

[0074] 4. DPP4 knockout has a tendency to reduce pulmonary fibrosis in RA-ILD mice

[0075] The analysis of the GEO database and RA-ILD model mice revealed that DPP4 may play an important role in RA-ILD and is positively correlated with fibrosis indicators. In this example, C57BL / 6J-SKG mice and corresponding Dpp4 knockout (hereinafter referred to as SKG×Dpp4 - / - ) mice were intraperitoneally injected with mannan for 12 weeks to establish an RA-ILD model. The nucleotide sequence of the interfering RNA used to knock out the Dpp4 gene is shown in SEQ ID NO.31 or SEQ ID NO.34. The modeling operation was the same as above to explore the effect of Dpp4 knockout on lung tissue fibrosis in RA-ILD mice. Related results are shown in Figure 9-10 ;in, Fig. 9 SKG and SKG×Dpp4 are shown - / - Statistical graph of HS score and Aschoff score of mouse lung tissue; Fig.10 SKG and SKG×Dpp4 are shown - / - Statistical chart of lung tissue fibrosis indicators in mice 12 weeks after intraperitoneal injection of mannan, from left to right: Col1a1, Fn1, Tgfb1 (or Tgf-β), and proline (hydroxyproline).

[0076] The above results showed that the expression of Tgfb1 in lung tissue was significantly reduced after Dpp4 knockout, and the HS score, Aschoff score and other fibrosis indicators showed a downward trend, indicating that Dpp4 knockout had an inhibitory effect on lung fibrosis in RA-ILD mice.

[0077] 5. DPP4 knockout reduces the activation ability of lung fibroblasts

[0078] The effect of Dpp4 knockout on lung fibroblasts was explored by in vitro culture. Specifically:

[0079] First, extract Dpp4 from WT mice and - / - Mouse lung primary fibroblasts: Mouse lung tissue was washed to remove blood clots on the surface, the lung tissue was cut into pieces, and 1 mL of enzyme solution (containing Ca 2+ Mg 2+ Dissolve type I collagenase and DNase I (2 mg / mL) in HBSS and resuspend the lung tissue fragments, transfer them to a 15 mL centrifuge tube, and then add 2 mL of enzyme solution. Digest at 37°C for 30 min; after digestion, use an equal amount of culture medium containing 10% FBS to stop digestion, and grind the undigested tissue into a single cell suspension. Use a 70 μm sterile filter to filter the tissue into a 50 mL centrifuge tube while grinding, and rinse with PBS during grinding until only white fibrous tissue remains on the filter. Then centrifuge at 300g for 7 min. After centrifugation, discard the supernatant. Add 1 mL of red blood cell lysis buffer, mix well, and let stand at room temperature for 5 min. Then add 1 mL of PBS to stop lysing red blood cells. Then centrifuge at 300g for 7 min. Resuspend the cells with 6-7 mL of DMEM complete culture medium containing 10% FBS and 1× double antibody, spread them in a 10 cm cell culture dish, spread the cells evenly using the "cross method", and place them in the incubator. After 3 days, change the medium of the cells, remove the medium, add 5 mL of sterile PBS, shake gently, remove the PBS, and repeat the washing 2-3 times. After washing, add 6-7 mL of DMEM complete medium containing 10% FBS and 1× double antibody again. After another 3 days, pass the cells. The passage of mouse lung tissue primary fibroblasts generally does not exceed 3 generations.

[0080] Stimulation of primary lung fibroblasts with TGF-β: DMEM medium containing 10% FBS was used to culture cells until they adhered to the wall and grew to a cell density of about 80%, and then TGF-β was added for stimulation (with a concentration gradient of 10 ng / mL, 20 ng / mL and 30 ng / mL) for 24 hours. Total RNA was then extracted from the cells and RT-PCR was performed to detect the expression levels of αSMA, Col1a1, Fn1 and TGF-β receptors Tgfbr1 and Tgfbr2. The expression of primary lung fibroblasts (Ki67 + cell proliferation capacity, related results are shown in Fig.11 Among them, Figure A shows the mRNA expression of fibrosis indicators in primary lung fibroblasts of wild-type mice and Dpp4 knockout mice after stimulation with TGF-β, Figure B shows the statistical chart of the proliferation ability of primary lung fibroblasts of wild-type mice and Dpp4 knockout mice after stimulation with TGF-β, and Figure C shows the expression of TGF-β receptors in primary lung fibroblasts of wild-type mice and Dpp4 knockout mice after stimulation with TGF-β.

[0081] The process of fibroblast activation and differentiation into myofibroblasts plays an important role in the pathogenesis of interstitial lung disease. This example found that compared with wild-type mice, Dpp4 - / - The activation and differentiation ability of mouse fibroblasts is reduced, which is reflected in the increased expression levels of αSMA, Col1a1 and Fn1 in wild-type mouse fibroblasts under TGF-β stimulation, and the significantly lower expression levels of αSMA, Col1a1 and Fn1 in DPP4 knockout mouse fibroblasts under TGF-β stimulation than in wild-type mice. In addition, Dpp4 knockout significantly reduced the activation ability of mouse primary lung fibroblasts induced by TGF-β.

[0082] The present invention reveals the potential mechanism and important role of DPP4 in regulating pulmonary fibrosis in RA-ILD, and confirms that DPP4 can affect the progression of fibrosis in RA-ILD by affecting fibroblast function. By reducing the expression level of DPP4, the activation ability of fibroblasts can be directly inhibited, thereby inhibiting the occurrence of fibrosis. This suggests that DPP4 is expected to be a therapeutic target for RA-ILD, providing new ideas for the research and development of RA-ILD disease drugs.

[0083] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. Use of a reagent for detecting the expression level of dipeptidyl peptidase-4 in the preparation of an auxiliary diagnostic reagent or kit for RA-ILD.

2. Use of the reagent for detecting the expression level of dipeptidyl peptidase-4 according to claim 1 in the preparation of an auxiliary diagnostic reagent or kit for RA-ILD, characterized in that: The reagent for detecting the expression level of dipeptidyl peptidase-4 is selected from at least one of a primer pair that specifically amplifies the dipeptidyl peptidase-4 gene or an antibody that specifically binds to the dipeptidyl peptidase-4 protein; wherein the nucleotide sequences of the upstream and downstream primers of the primer pair are shown in SEQ ID NO.3-4.

3. Use of a reagent for downregulating the expression level of dipeptidyl peptidase-4 in the preparation of a drug for treating RA-ILD, characterized in that: The agent for downregulating the expression level of dipeptidyl peptidase-4 is selected from siRNA, and the nucleotide sequence of the siRNA is shown in SEQ ID NO.31 or SEQ ID NO.34.